Hypertension (high blood pressure) Board decisions

The Board denied service connection for hypertension and remanded the claim for diabetes mellitus, type II under 38 U.S.C. § 1151.

The Board denied service connection for hypertension, sinusitis, chronic fatigue syndrome (CFS), a cervical spine disability, a bilateral ankle disability, a bilateral knee disability, and a bilateral shoulder disability as there was no evidence of current diagnoses or medical nexus to active service.

The Board granted the restoration of a 10 percent rating for hypertension, effective March 1, 2024, as the reduction was improper.

The appeal for service connection for a right hand disability, hypertension, and lung cancer was dismissed due to improper substitution of the claimant.

The Board denied service connection for hypertension as the evidence did not support a finding that it had its onset during active service or within a year of separation, nor was there any other basis to link it to service.

The Board denied service connection for bilateral tinnitus and bilateral hearing loss due to the lack of a current diagnosis, and remanded claims for diabetes mellitus type II and hypertension associated with herbicide exposure for further development.

The Board remands the claim for service connection for hypertension to obtain an additional opinion on whether the Veteran's hypertension was aggravated by his service-connected low back disability.

The Board denied service connection for hypertension and hypothyroidism, as the evidence did not support a finding that these conditions were related to the Veteran's service on a non-presumptive basis.

The Board of Veterans' Appeals remands the service connection claims for various conditions due to a need for an updated certificate of discharge determination and outstanding VA treatment records.

The Board denied earlier effective dates for TDIU and DEA benefits, service connection for various conditions, and higher initial disability ratings.

The Board denied service connection for bronchial asthma and denied increased ratings for several disabilities, while granting a 10 percent rating for hypertension.

The Board granted a 10 percent rating for hypertension, but denied higher ratings for scars of the left and right thigh, plantar fasciitis of the left foot, hip and knee osteoarthritis, and service connection for various conditions including erectile dysfunction, lumbar spine pain, TBI, and cervical spine pain.

The Board granted a rating of 50 percent for major depressive disorder with alcohol use disorder and cognitive impairment from May 1, 2017 to December 10, 2019; denied a rating in excess of 70 percent from December 11, 2019 to February 6, 2023. The Board granted ratings of 20 percent for right and left lower extremity sciatic nerve peripheral neuropathy from May 1, 2017 to February 6, 2023; denied a rating in excess of 20 percent on and after February 7, 2023. The Board granted an initial 10 percent rating for hypertension effective August 10, 2022.

The Veteran withdrew the appeal for all service connection claims, and the Board dismissed the case.

The Board granted service connection for hypertension, Hepatitis C, and cirrhosis of the liver. Atrial fibrillation was denied.

The Board denied the veteran's claims for increased ratings and service connection, as well as a TDIU.

The appeal concerning the service connection for various conditions was withdrawn by the Veteran before the Board promulgated a decision.

The Board granted direct service connection for GERD, hypertension, and a heart attack and its residuals due to exposure to contaminated water at Camp Lejeune. The right hip cyst with osteoarthritis was granted as secondary to the service-connected plantar fasciitis.

The Board denied the Veteran's claims for eligibility for specially adapted housing, a special home adaptation grant, and financial assistance in purchasing an automobile or other conveyance and adaptive equipment. The claim of CUE in the September 14, 2017, rating decision was also denied.

The Board granted an initial 10 percent rating for hypertension but denied a compensable evaluation for chronic kidney disease, stage III.